Western blotting bands shown in Figure 5(a) revealed that the protein levels of ERK and FOXO3 in breast cancer cells were notably lower in the ulinastatin group than in the control group (∗p < 0.05, ∗p < 0.05), and they were also remarkably lower in the ulinastatin+ERK inhibitor group than in the ulinastatin group (#p < 0.05, #p < 0.05), suggesting that ulinastatin inhibits the protein expressions of ERK and FOXO3 in the ERK signaling pathway. The gene discussed is FOXO3; the disease is breast carcinoma.